利伐沙班作為一種特異性凝血因子Xa抑制劑在臨床上被廣泛應(yīng)用于抗凝的預(yù)防及治療中。然而，在臨床應(yīng)用過程中，利伐沙班與其他藥物合用所致的出血風(fēng)險仍需密切監(jiān)視。聚焦藥物代謝酶及轉(zhuǎn)運(yùn)體，分別從利伐沙班與心血管系統(tǒng)藥物、抗腫瘤藥物、以及代謝靶點(diǎn)相關(guān)藥物合用等方面系統(tǒng)綜述藥動學(xué)介導(dǎo)的利伐沙班相關(guān)藥物-藥物相互作用的研究進(jìn)展，旨在為利伐沙班的臨床安全合理用藥提供更科學(xué)、更直接的指導(dǎo)依據(jù)。

Rivaroxaban as a specific Xa inhibitor is widely applied to the prevention and treatment of clinical anticoagulation. However, the risk of bleeding caused by the combination of rivaroxaban with other drugs still needs to be closely monitored in clinical application. This review focuses on the metabolic enzymes and transporters, systematically summarizes the progress of rivaroxaban related DDIs mediated by pharmacokinetics from the aspects of the applications combined with cardiovascular drugs, anti-cancer drugs and drugs related to metabolic targets and so on, aiming to provide more significant and direct guidance for rivaroxaban clinical application.

國家自然科學(xué)基金資助項目（81874324）；遼寧省興遼英才青年拔尖人才項目（XLYC1907103）